Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Keppra 250 mg film-coated tablets
Medicines register · Ireland

Keppra 250 mg film-coated tablets

Authorisation EU/1/00/146/001-005 · UCB Pharma S.A.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
UCB Pharma S.A. (all products →)
Active substance
Levetiracetam
Clinical trials
14 clinical trials →
Dosage form
Film-coated tablet
Route of administration
Not Currently Available
ATC code
N03AX14
First authorised
29/09/2000
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Levetiracetam: supply and approvals

45 authorised products on the HPRA list contain Levetiracetam. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
20 supply notices, e.g. Levetiracetam HEXAL 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung (6 Jul 2026 to 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 146. It has been authorised for 26 years (since 29 September 2000). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Levetiracetam in Ireland

44 other products on the HPRA list contain Levetiracetam, from 15 licence holders; 5 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Levetiracetam 100 mg/ml Concentrate for solution for infusionNoridem Enterprises LimitedNational authorisation (PA)Marketed
Levetiracetam Clonmel 1000 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Levetiracetam Clonmel 250 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Levetiracetam Clonmel 500 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Levetiracetam Thame 100 mg/ml oral solutionSyri Pharma Limited t/a Thame LaboratoriesNational authorisation (PA)Marketed
Keppra 100 mg/ml concentrate for solution for infusionUCB Pharma S.A.Centralised EU authorisationNot stated
Keppra 100 mg/ml oral solutionUCB Pharma S.A.Centralised EU authorisationNot stated
Keppra 1000 mg film-coated tabletsUCB Pharma S.A.Centralised EU authorisationNot stated
Keppra 500 mg film-coated tabletsUCB Pharma S.A.Centralised EU authorisationNot stated
Keppra 750 mg film-coated tabletsUCB Pharma S.A.Centralised EU authorisationNot stated
Larofec 1000 mg film-coated granules in sachetC4 health GmbHNational authorisation (PA)Not marketed
Larofec 250 mg film-coated granules in sachetC4 health GmbHNational authorisation (PA)Not marketed

All 45 products with Levetiracetam →

The licence holder

UCB Pharma S.A. holds 42 products on the HPRA list, with 13 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.